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The MO25 scaffolding protein operates as critical regulator of a number of STE20 family protein kinases
(e.g. MST and SPAK isoforms) as well as pseudokinases (e.g. STRAD isoforms that play a critical role in
activating the LKB1 tumour suppressor). To better understand how MO25 interacts and stimulates the
activity of STE20 protein kinases, we determined the crystal structure of MST3 catalytic domain (residues
19–289) in complex with full length MO25b. The structure reveals an intricate web of interactions
between MST3 and MO25b that function to stabilise the kinase domain in a closed, active, conformation
even in the absence of ATP or an ATP-mimetic inhibitor. The binding mode of MO25b is reminiscent of the
mechanism by which MO25a interacts with the pseudokinase STRADa. In particular we identiﬁed inter-
face residues Tyr223 of MO25b and Glu58 and Ile71 of MST3 that when mutated prevent activation of
MST3 by MO25b. These data provide molecular understanding of the mechanism by which MO25 iso-
forms regulates the activity of STE20 family protein kinases.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. 1. Introduction face aligned with highly conserved residues and a less conservedMouse Protein-25 (MO25) is a highly conserved scaffolding pro-
tein originallydiscoveredas ahighlyevolutionary conservedprotein
expressed at the early cleavage stage of mouse embryogenesis [1].
Mammals possess two closely related isoforms termed MO25a and
MO25b, which share 79% sequence identity [2]. One of the most
investigated roles of MO25a is as one of the core components of
the LKB1 tumour suppressor complex that regulates proliferation,
metabolism and polarity by phosphorylating and stimulating 14
AMPK family protein kinases [3]. The LKB1 kinase complex is a het-
erotrimer consisting of the protein kinase LKB bound to a catalyti-
cally inactive pseudokinase termed STRAD (of which there are two
isoforms termed STRADa and STRADb) andMO25 [4–6]. Association
of LKB1withMO25and STRADstimulates LKB1proteinkinase activ-
ity [2,4] and is essential for activation of AMPK family kinases [7,8].
The crystal structure of monomeric MO25a revealed that it con-
sists of seven helical repeats arranged in a distinctive horseshoe
shapedistantly related to theArmadillo proteinswith a concave sur-r Inc.
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Open access under CC BY license. convex surface fold [9]. Subsequent work analysing the structure
of the heterodimeric STRAD:MO25 [10] and the heterotrimeric
LKB1:STRAD:MO25 [11] complexes showed that the concave sur-
face of MO25 formed an intricate network of interactions with the
aC-helix of STRADa, reminiscent of the mechanism by which
CDK2 interacts with cyclin A. MO25a acts to stabilise STRADa in
an active conformation with an ordered T-loop that binds ATP and
hence capable of binding to and activating LKB1 [10,11]. Activation
of LKB1 is prevented by mutations that are predicted to destabilise
the active conformation of STRADa namely those that prevent bind-
ing of STRADa toMO25a and ATP [11].MO25a also stimulates LKB1
catalytic activity bybindingdirectlywith the T-loopof LKB1 and sta-
bilises it in an active conformation [11].
Recent work has demonstrated thatMO25 isoforms also interact
with at least ﬁve distinct protein kinases that are related to STRADa/
STRADb and belong to the STE20 branch of mammalian kinases.
These include SPAK and OSR1 that are important regulators of ion
homeostasis and blood pressure [12] as well as MST3, MST4, YSK1
that controlmorphogenesis and polarity [13,14]. The catalytic activ-
ity of SPAKandOSR1 is stimulatedover 100-foldbybinding toMO25
isoforms, whereas MST3, MST4 and YSK1 are activated three- to
four-fold. To learn more about the roles of MO25 in regulating
STE20 protein kinases we have co-crystallised the catalytically ac-
tive kinase domain of MST3 with MO25b. The structure reveals the
intricate mechanism by which MO25b binds to MST3 and enables
the construction of mutants that prevent activation of MST3 by
MO25b.
Table 1
Data collection and reﬁnement statistics.
PDB ID 3ZHP
Space group P21
No. of molecules in the asymmetric unit 2
Unit cell dimensions
a, b, c (Å)
a, b, c ()
64.8, 120.3, 98.9
90.0, 99.7, 90.0
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2.1. Reagents
Tissue-culture reagents were from Life Technologies. P81 phos-
pho-cellulose paper was from Whatman and [c-32P]-ATP was from
Perkin Elmer. Myelin basic protein was from Sigma.Data collection
Beamline Diamond I04-1
Resolution range (Å)a 63.88–2.90
(3.06–2.90)
Unique observationsa 32,108 (4687)
Average multiplicitya 4.3 (4.3)
Completeness (%)a 96.8 (97.3)
Rmerge
a 0.07 (0.78)
Mean ((I)/r(I))a 10.0 (1.7)
Reﬁnement
Resolution range (Å) 63.96–2.90
R-value, Rfree 0.23, 0.26
r.m.s. deviation from ideal bond length (Å) 0.009
r.m.s. deviation from ideal bond angle () 0.99
Ramachandran outliers
Most favoured
0.61%
95.57%
a Values within parentheses refer to the highest resolution shell.2.2. Expression and puriﬁcation of MST3 and MO25b complex for
crystallisation
MST3 and MO25b clones were transformed into E. coli BL21
(DE3) competent cells containing the pRARE2 plasmid from the
commercial Rosetta strain, and the transformants were used to
inoculate 50 ml of Luria–Bertani (LB) medium containing 50 lg/
ml kanamycin (MST3) or 100 lg/ml ampicillin (MO25b) with the
addition of 34 lg/ml chloramphenicol. These cultures were incu-
bated overnight at 37 C. For each protein, 3 10 ml of the over-
night culture was used to inoculate 3 1 l of LB medium with
40 lg/ml kanamycin or 80 lg/ml ampicillin and grown at 37 C un-
til an OD600 of 0.4–0.5 was reached. The temperature was then re-
duced to 20 C. When the OD600 reached 0.6, expression was
induced by addition of 0.5 mM IPTG. Expression was continued
overnight. The cells were harvested by centrifugation. The MST3
cells were resuspended in Binding Buffer. The MO25b cells were
resuspended in Buffer 1. The resuspended cells were frozen until
further use.
For puriﬁcation the cells were thawed and lysed by sonication
on ice. PEI (polyethyleneimine) was added to a ﬁnal concentration
of 0.15% and the cell debris and precipitated DNA were spun down.
MST3 was puriﬁed by passing the supernatant through a gravity
column of 5 ml Ni-Sepharose resin (GE Healthcare). The resin
was washed with 50 ml of Binding Buffer containing 1 M NaCl
and 40 mM imidazole, 50 ml of Binding Buffer containing 60 mM
imidazole before the protein was eluted with 25 ml of Binding Buf-
fer containing 250 mM imidazole. The eluted protein was further
puriﬁed by gel ﬁltration chromatography using an S200 16/60 col-
umn (GE Healthcare) in 20 mM Tris pH 7.5, 200 mM NaCl, 0.5 mM
TCEP. MO25b was puriﬁed by passing the supernatant through a
gravity column of 5 ml Glutathione-Sepharose (GE Healthcare).
The resin was washed with 6x 10 ml of Buffer 1 and 6x 10 ml of
Buffer 2. Prescission protease was added to the resin and incubated
overnight. The MO25b protein was then eluted with 50 ml of
Buffer 2.
The MST3 protein was concentrated to 2.4 mg/ml and the
MO25b protein was concentrated to 7.8 mg/ml. The concentrated
proteins were mixed in an equimolar ratio and injected onto an
S200 16/60 gel ﬁltration column pre-equilibrated in 20 mM Tris
pH 7.5, 200 mM NaCl, 0.5 mM TCEP. Fractions containing the pro-
tein complex were pooled and concentrated to 9.7 mg/ml. Protein
identities were conﬁrmed by mass spectrometry under denaturing
conditions (MST3: expected 33257 Da, observed 33257 Da;
MO25b: expected 39225 Da, observed 39225).2.3. Structure determination
Crystals were obtained using the sitting drop vapour diffusion
method at 4 C. The protein (9.7 mg/ml) was mixed 1:1 with a res-
ervoir solution containing 0.2 M Na/KPO4, 10% PEG 3350, 10% Eth-
ylene Glycol in a drop size of 150 nl. Crystals were cryoprotected
by transfer into reservoir solution containing 25% ethylene glycol.
Crystals were then ﬂash-frozen in liquid nitrogen and diffraction
data were collected at Diamond beamline I04-1. Data collection
statistics can be found in Table 1.The diffraction data was indexed and integrated using MOSFLM
[15] and scaled using SCALA [16]. The structure was solved by
molecular replacement using PHASER [17]. The search models used
were PDB IDs 3CKW (human MST3) and an ensemble of 3GNI,
1UPK and 2WTK (MO25). Two molecules of the MST3:MO25b com-
plex were present in the asymmetric unit. The model was built in
Coot [18] and reﬁned with REFMAC5 [19]. Tight NCS restraints
were applied during the reﬁnement, which included reﬁnement
of TLS parameters.
Further details on general methods and plasmids; Buffers, cell
culture, transfection and immunoprecipitation, expression MST3
and kinase activity measurements, expression and puriﬁcation of
MO25 mutants in E. coli is provided in the supplementary section.
3. Results and discussion
3.1. Description of the MST3:MO25 complex
We crystallised a complex of an MST3 catalytic fragment (resi-
dues 19–289) with full length MO25b. The MST3 numbering is gi-
ven according to that of isoform b (NCBI NP_001027467.2)
(Table 1). The 19–289 fragment encompasses the kinase domain,
but lacks the C-terminal non-catalytic domain that contains a
WIF motif (residues 325–327 in MST3). The equivalent residues
in STRADa (WEF: residues 429-431) bind to a C-terminal hydro-
phobic pocket on MO25a [9,20].
Two copies of the MST3:MO25b complex occupied the crystal-
lographic asymmetric unit and in each case the same binding
arrangement for MST3 and MO25b was observed. The domain
arrangement resembles that of the previously published complex
between STRADa and MO25a [10]. MO25b binds to MST3 adjacent
to the helix aC which has a key role regulating kinase activity in
most kinases. Structural comparison with the STRADa:MO25a
complex revealed additional interactions involving MST3 strands
b4 and b5 (Fig. 1). These interactions primarily involve three out
of the six structural repeats of MO25b. The residues of MO25b that
interact with MST3 are highly conserved in both MO25 isoforms
(Fig. 2B).
The extensive number of interactions between MST3 and
MO25b can be divided into three sections: (a) Hydrogen bonding
interactions involving the central part of aC and strand b4. There
Fig. 1. Structure of the MST3:MO25b complex. (A) Structural overview with MO25b coloured green, the N-terminal lobe of MST3 coloured brown and the C-terminal lobe
coloured blue. The activation loop and helix aC are coloured red. (B) As (A) with an approximately 90 rotation. (C, D) Two views of the hydrogen bonding network that links
the loop between strand b3 and aC with MO25b. (E and F) Two views of the interactions between MST3 and MO25b involving aC and b3 of MST3. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. Sequence alignments of (A) Relevant regions of kinases activated by MO25, and (B) MO25 isoforms. Residues of MST3 or MO25b that are on the interface between
MST3 and MO25b are marked with a black ⁄ above the alignment. Known phosphorylation sites of MST3 are marked with a red ⁄. Full sequence alignments can be seen in the
Supplementary material. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Asp178 of MO25b, as well as between the side-chains of Gln68
and Ser181 of MO25b (Fig. 1E and F). (b) Central hydrophobic
interactions involving the N-terminal part of aC and residues fromstrands b3, b4 and b5. Leu57, Ile64, Leu90, Leu95 from MST3 form
this core hydrophobic patch with Phe177 and Val223 from MO25b
(Fig. 1E and F). (c) A network of hydrogen bonding interactions
involving the loop between MST3 strand b3 and aC. Glu58 is at
Fig. 3. Superimposition of MST3:MO25b structure with STRADa:MO25a. MST3 is
shown in cyan, and STRADa in yellow with its C-terminal region including WEF
motif in magenta. MO25b bound to MST3 is shown as a green surface, and MO25a
bound to STRADa is shown as a brown surface. (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
Y. Mehellou et al. / Biochemical and Biophysical Research Communications 431 (2013) 604–609 607the centre of this network, forming hydrogen bonds to the back-
bone nitrogen atom of MO25b Asn268 and the side-chain of
MO25b Ser266. Additional hydrogen bonds are formed between
the side-chains of Asp62 and MO25b Arg226, and between the
backbone oxygen of Leu57 and MO25b Tyr222 (Fig. 1C and D).
These results suggest that MO25b activates MST3 by stabilisa-
tion of aC in an active position. In inactive kinases it is often pos-
sible for aC to assume an outward position, displaced away from
the ATP binding site. As MO25b binds to aC and also to b4 and
b5 it ﬁxes the position of aC relative to b4, b5 and the rest of the
N-terminal lobe of the kinase domain. Therefore the binding en-
ergy of MO25b to MST3 is used to pre-organise the catalytically
important regions of the kinase domain, a mechanism frequently
observed for activators of kinases. The stabilisation of aC also leads
to the partial stabilisation of the activation loop via a number of
interactions between them, in particular in the region around the
DFG motif. However, MST3 will be activated further by auto-phos-
phorylation on Thr178.
The binding angle between theMST3 kinase domain andMO25b
is slightly different to that between STRADa andMO25a (Fig 3). This
differencemaybehowever inﬂuencedbydifferences in crystal pack-
ing environment, but it might also be a consequence of the lack of a
WEFpeptidebinding toMO25b. Thedifference in binding angle does
not signiﬁcantly change the surface area of interaction, or the angle
of the key kinase regulatory element helix aC.
3.2. Mutational analysis of interface residues
To assess the importance of the interface residues in mediating
the activation of full length MST3 by MO25, we compared basal
and MO25-stimulated activity of full length MST3 and the crystal-
lised MST3 (19–289) fragment. The data showed that the full
length MST3 was activated by both MO25a and MO25b isoforms
as previously reported [20], whilst the crystallised MST3 (19–
289) fragment was devoid of catalytic activity and the addition
of either MO25a or b did not result in any further activation. A
fragment of MST3 that encompasses the WIF motif (i.e. residues
19–319) lacking in the crystallised MST3 displayed similar basal
and MO25 induced activity to full length MST3 (Fig. 4A).
The crystal structure of MST3 (19–289) in complex with MO25b
was used to design mutations in full length MST3 as well as MO25
isoforms to insight into the residues needed for binding betweenthe two proteins, which result in an increased kinase activity of
MST3 by MO25. We ﬁrst mutated residues on full length MST3 that
were implicated to interact with MO25b (Glu58, Ile71, Tyr85,
Ser88, and Leu90) and tested how this impacted on the basal
MST3 activity and its activation by MO25a. This revealed that
mutation of Glu58 or Ile71 to Ala did not affect basal activity but
prevented MST3 activation by MO25a. Mutation of Tyr85 to Ala
markedly inhibited basal MST3 activity, while mutating Tyr85 to
Phe maintained basal activity and partially supressed activation
by MO25a. Mutation of Ser88 and Leu90 markedly reduced basal
MST3 activity but the activity of these mutants was still enhanced
2- to 3-fold by MO25a (Fig. 4B). We also mutated a number of res-
idues on MO25a implicated in binding to MST3. This revealed that
mutation of MO25a Tyr223 that interacts with MST3 Leu57 abol-
ished activation of MST3 by MO25a, similarly to the previously re-
ported R227A + M260A double mutant [20] (Fig. 4C).
Three of these mutations reduced basal MST3 activity signiﬁ-
cantly. The aromatic ring of Tyr85 is probably important for stabi-
lisation and binding of strands b4 and b5 against aC, since Y85F
retained basal activity compared to Y85A, which reduced basal
activity (Fig. 4B). In the case of S88A and L90A, which also reduced
basal activity, the same explanation would apply: secure binding of
b4 to b5 is presumably important for the stability of the N-terminal
lobe. The prevention of MO25 activation by the I71A and E58A mu-
tants shows that, respectively, the central hydrophobic binding
interface and the interactions between the b3–aC loop and MO25
are both essential for activation by MO25. The essential nature of
the b3–aC loop interactions with MO25 are emphasised by the
inability of MO25a Y223A or Y223F to activate MST3.
3.3. Comparison of MST3 activation to OSR1 and SPAK
The kinases OSR1 and SPAK are activated around 25 times more
strongly by MO25 than are MST3, MST4 and YSK1. Analysis of the
MST3 residues at the interface with MO25b reveals that many of
the interacting residues are conserved across all ﬁve of these ki-
nases (Fig. 2A). Of the ﬁve MST3 residues on b4 and b5, four are
completely conserved (Tyr85, Ser88, Leu95) while Leu90 is conser-
vatively substituted by Val in OSR1 and SPAK. Of the six MST3 res-
idues on b3 and aC that interact with MO25b, three are completely
conserved (Leu57, Glu58 and Ile71) and two are conservatively
substituted in OSR1 and SPAK (Asp62 (as Thr) and Ile64 (as
Met)). However, one key difference is Gln68 which is replaced by
Leu in OSR1 and SPAK. Gln68 provides a polar side-chain at the
centre of an otherwise hydrophobic patch (Fig. 1E and F). Replace-
ment of Gln68 with Leu would signiﬁcantly increase the interact-
ing surface that stabilizes this hydrophobic interaction. This
would presumably increase the afﬁnity of MO25 for OSR1 and
SPAK and therefore provide more binding energy for stabilisation
of a catalytically active kinase conformation.
There is one other potentially key difference between MST3,
MST4 or YSK1, and OSR1 or SPAK, which is that the former all have
a WXF motif, while the latter have a WEW motif. STRADa also has
a WXF motif like MST3, and the structure of STRADa with MO25a
[10] suggests that replacement of WXF with WXW may increase
afﬁnity by increasing the hydrophobic interaction area between
the WXF motif and MO25a, and possibly providing an additional
hydrogen bond to Asn261 of MO25a.
3.4. The C-terminal non-catalytic domain of MST3 is essential for
activity
Our results show that the C-terminal non-catalytic region of
MST3 is essential for activity, even in the absence of MO25. How-
ever, mutation of the Trp and Phe residues in the WIF motif to Ala
in full length MST3 or MST4 only reduced basal kinase activity
Fig. 4. Mutational analysis of how truncation of non-catalytic WIF-motif of MST3 and interface residues impacts on basal kinase activity and activation by MO25 isoforms. (A
and B) The indicated wild type and mutant forms of MST3 were puriﬁed from HEK293 cells and were assayed in the presence or absence of ten-fold excess of wild type full
length MO25a or MO25b, puriﬁed from E. coli. The activity in the presence of MO25a is reported relative to the activity measured in the absence of MO25a. Assays were
undertaken in triplicate and data presented as mean ± s.d. Coomassie gels are shown to illustrate the relative levels of wild type and mutant. (C) as in (A) except that the wild-
type or indicated mutants of MO25a were employed.
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addition of MO25a [20]. Moreover, mutation of the equivalent res-
idues in the WIF motif of YSK1 barely affected basal or MO25 stim-
ulated activity [20]. Thus residues other than the WIF motif may
also account for lack of activity of crystallised forms of MST iso-
forms. The published structures of MST3 with a variety of co-fac-
tors (ADP, adenine, ADP + Mn) [21], as well as other unpublished
MST3 structures in the PDB (3CKW, 3CKX), were all also derived
from MST3 constructs lacking the C-terminal WIF motif. The struc-
ture of YSK1 (PDB ID 2XIK) was also derived from a construct lack-
ing a C-terminal WIF motif, as were the structures of MST4 [22].
Further work is therefore warranted to elucidate the mechanism
by which the non-catalytic domain regulates kinase activity of
these enzymes.
The structures of STRADa with MO25a [10,11] showed that the
C-terminal region including the WEF motif links the C-terminal
lobe of the STRADa kinase domain to the binding site on MO25a
located above the N-terminal lobe of STRADa. C-terminal exten-
sions to kinase domains that bind to the N-terminal lobe and acti-
vate the kinase are a feature of many kinases, in particular those of
the AGC family. For STRADa, and MST3, to make this connection in
an intramolecular way requires that this C-terminal region crosses
the front of the ATP binding site or the substrate-binding region.
Therefore in addition to stabilisation of the kinase domain by link-
ing the C-terminal lobe to the N-terminal lobe via MO25, there
may also be direct effects on interactions at the active site. In the
absence of MO25 the C-terminal extension to MST3 may also exert
its activating effect by interaction with these important regions, or
perhaps by binding of the WIF motif to a location elsewhere on the
kinase domain.3.5. Relevance to activation of MST3 substrates
MST3 has been reported to activate NDR2 protein kinase [23] by
phosphorylating the Thr of its hydrophobic motif (sequence
FLNYTY). Recently it has been reported that in addition to autop-
hosphorylating on Thr178 of its activation loop, MST3 also autop-
hosphorylates on Thr328 which is located just after the WIF motif
(sequence WIFTI) [24]. Clearly these sequence motifs have a strong
resemblance to each other, being of the formUx(12)UTU whereU
is a hydrophobic residue. It may be that in the mechanism of NDR2
phosphorylation an exchange takes place whereby the (phosphor-
ylated) MST3 WIF motif binds to NDR2 in place of its hydrophobicmotif, allowing the NDR2 hydrophobic motif to bind to the sub-
strate site on MST3. A recent paper has shown that in the fungi
Neurospora crassa the HYM1 (MO25) protein regulates COT1
(NDR), acting to scaffold the NDR kinase with its activating kinase
POD6 [25]. In ﬁssion yeast, it was reported that the equivalent pro-
tein Pmo25 (MO25) and the kinase Nak1 were required for activa-
tion of the kinase Orb6 (NDR) [26]. Orb6 has 50% sequence identity
to human NDR2 and has an equivalent hydrophobic motif FLGYTY,
while Pmo25 is 51%/52% identical to MO25a/MO25b and Nak1 is
51% identical to human MST3 (its closest relation) and also pos-
sesses a WEF motif followed by a potential phospho-acceptor (se-
quence WEFGT, amino acids 321–325). It therefore may be that
human MO25 would have an activating function for MST3 on
NDR, in an evolutionarily conserved mechanism.
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